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Abstract
Multiple Sclerosis (MS) is a neurodegenerative disorder characterized by a complex set of clinical
assessments. We use an unsupervised machine learning model called a Conditional Restricted Boltz-
mann Machine (CRBM) to learn the relationships between covariates commonly used to characterize
subjects and their disease progression in MS clinical trials. A CRBM is capable of generating digital
twins, which are simulated subjects having the same baseline data as actual subjects. Digital twins
allow for subject-level statistical analyses of disease progression. The CRBM is trained using data
from 2395 subjects enrolled in the placebo arms of clinical trials across the three primary subtypes
of MS. We discuss how CRBMs are trained and show that digital twins generated by the model are
statistically indistinguishable from their actual subject counterparts along a number of measures.
∗ jon@unlearn.ai
† Data used in the preparation of this article were obtained from the Multiple Sclerosis Outcome Assess-
ments Consortium (MSOAC). As such, the investigators within MSOAC contributed to the design and
implementation of the MSOAC Placebo database and/or provided placebo data, but did not participate
in the analysis of the data or the writing of this report.
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I. INTRODUCTION
Statistical models that characterize and predict disease progression have the potential
to become important tools for research and management of complex, chronic indications
like Multiple Sclerosis (MS). In the context of clinical research, for example, statistical
models of disease progression could be used to simulate different study designs [1], to identify
patients who are likely to progress more rapidly than typical patients [2], or as external
comparators in early stage clinical trials [3]. Despite the availability of Disease Modifying
Therapeutics (DMTs) for MS, many clinical trials still compare experimental treatments to
placebo controls [4–7], which can deter patients from enrolling in those trials. At the same
time, the rich history of clinical trials in MS provides a high quality source of data about
disease progression under placebo or non-DMT control conditions, creating an opportunity
for statistical models to further the clinical understanding of MS and better inform the
design and analysis of trials [8].
Ideally, a statistical model of disease progression would describe all of the clinical char-
acteristics that are relevant for a patient with MS, how these characteristics change through
time, their inter-relationships, and their variabilities. That is, in more technical terms, it
would describe a joint probability distribution of the relevant clinical characteristics over
time. Throughout, we refer to a sample drawn from this distribution as a digital subject.
By definition, therefore, a digital subject is a computationally generated clinical trajectory
with the same statistical properties as clinical trajectories from actual patients. The pri-
mary advantages of digital subjects, in comparison to data from actual patients, are that
they present no risk of revealing private health information and make it possible to quickly
simulate patient cohorts of any size and characteristics.
Although the ability to create digital subjects enables one to simulate cohorts of patients,
there are many applications for which one would like to make predictions about a particular
patient. A statistical model that is able to generate digital subjects can also be used for
individual patients by generating digital subjects that have the same clinical characteristics
as the patient of interest at a given date (such as the start of a clinical study). We refer to
a digital subject that has been generated in order to match a particular patient as a digital
twin of that patient, in analogy with the usage of the term “digital twin” in engineering
applications [9]. For example, if the statistical model represents disease progression on a
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placebo, then a digital twin provides a potential outcome – i.e., what would likely happen
to this patient if she/he were given a placebo in a clinical trial? In more technical terms,
a digital twin is a sample from a joint probability distribution of the relevant clinical char-
acteristics at future times conditioned on the values of those characteristics at a previous
time. We note that it is possible to generate multiple digital twins for any patient.
Evaluating the quality of a model that generates digital subjects or digital twins is more
complex than the evaluation of traditional machine learning models. For example, it is
necessary, but not sufficient, that the means, standard deviations, correlations, and auto-
correlations of all covariates computed from cohorts of digital subjects agree with those
computed from cohorts of actual subjects. Here, we introduce a concept called statistical in-
distinguishability. Digital subjects, or digital twins, are statistically indistinguishable from
actual subjects if a statistical procedure designed to classify a given clinical record as a
digital subject or an actual subject performs consistently with random guessing.
Creating a statistical model that can generate digital subjects and digital twins that are
statistically indistinguishable from actual patients is no small feat, but recent advances in
generative neural networks make it possible to train generative models for complex prob-
ability distributions [10–12], including time-dependent clinical data [2]. Here, we train a
probabilistic generative neural network to create digital subjects with MS using a database
of placebo arms aggregated across 7 historical clinical trials [8] covering many clinically
relevant covariates including demographic information, relapses, the Expanded Disability
Status Scale (EDSS) [13], and functional tests. To illustrate the concept of a digital subject
for MS, Figure 1 shows two digital subjects generated by the model with the same starting
characteristics (i.e., the two subjects are twins).
As a complex neurodegenerative disorder with a course that is “highly varied and unpre-
dictable” [14], MS is both a good test-case for the application of machine learning methods
as well as a disease area that would benefit from improved characterization and prediction
of disease progression. Previous models for disease progression in MS include survival mod-
els [15–17], Markov models [18–20], and other methods [21–25]. Most of these studies aim to
predict the progression of either the total EDSS score or relapses as they are common ways
to characterize disease severity. To our knowledge, our approach is the first that models
comprehensive subject-level clinical trajectories that go beyond the total EDSS score.
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Multiple Sclerosis Digital Subject Example
Age (years): 44 MS type: RRMS
Sex: Female Relapses in past year: 1
Race: White Relapses in past 2 years: 2
Region: Europe
Twin A
Time (months) Baseline 3 6 9 12 15 18 21 24 27 30 33 36
Had Relapse N N N N N N N N N N N N N
KFSS Pyramidal 2 2 3 2 2 2 3 3 3 3 2 2 2
KFSS Sensory 1 2 2 1 2 2 2 0 2 1 3 1 1
KFSS Bowel Bladder 1 1 2 1 2 2 1 2 1 1 2 2 1
KFSS Visual 1 0 1 1 1 0 1 1 1 1 3 3 3
KFSS Cerebellar 2 1 1 1 1 2 2 2 2 2 1 1 1
KFSS Brain Stem 1 0 1 1 1 2 2 2 2 1 1 1 1
KFSS Mental 0 0 0 0 0 0 0 0 1 0 1 2 2
Ambulation Score 0 0 0 0 0 0 0 0 0 0 0 1 0
EDSS Total Score 2.5 2.5 3.5 2 3 3.5 4 4 4 3.5 4 5 3.5
Timed 25-Foot Walk (s) 10.1 6.0 7.2 7.2 5.4 5.4 4.5 3.4 6.5 5.3 5.7 7.5 5.7
9-Hole Peg Test (Dominant Hand, s) 30.9 28.5 38.9 28.3 26.6 28.5 16.4 18.9 17.5 18.2 24.6 23.9 17.4
9-Hole Peg Test (Non-Dominant Hand, s) 43.3 30.7 39.1 26.5 22.7 22.7 26.8 28.5 32.0 19.7 18.3 23.4 21.7
PASAT, 3-second 50 58 59 59 55 59 51 57 57 59 60 59 59
Twin B
Time (months) Baseline 3 6 9 12 15 18 21 24 27 30 33 36
Had Relapse N Y N N Y N N N N N N N N
KFSS Pyramidal 2 2 2 2 3 3 2 3 4 4 4 4 4
KFSS Sensory 1 1 2 1 2 1 2 1 0 1 0 0 0
KFSS Bowel Bladder 1 1 1 0 1 0 1 0 0 0 0 0 0
KFSS Visual 1 1 1 1 2 1 0 0 0 0 0 0 0
KFSS Cerebellar 2 2 2 2 3 2 4 3 2 3 3 3 3
KFSS Brain Stem 1 2 1 2 3 2 2 2 1 1 1 0 1
KFSS Mental 0 2 2 2 1 1 0 0 0 0 0 0 0
Ambulation Score 0 0 0 0 2 3 1 2 1 3 4 3 3
EDSS Total Score 2.5 3 3 3 5.5 6 5 5.5 5 6 6.5 6 6
Timed 25-Foot Walk (s) 10.1 5.8 13.6 4.2 6.9 4.4 10.7 20.8 23.0 25.6 6.9 15.8 29.5
9-Hole Peg Test (Dominant Hand, s) 30.9 30.2 18.8 32.2 46.4 32.4 35.9 28.8 27.3 27.5 28.8 23.6 33.3
9-Hole Peg Test (Non-Dominant Hand, s) 43.3 41.9 32.8 26.2 36.9 29.7 24.7 20.3 31.4 22.3 24.9 27.0 41.4
PASAT, 3-second 50 46 32 55 48 57 50 59 47 52 37 24 40
FIG. 1. Example digital subjects for MS. Two digital subjects were sampled from the joint
probability distribution learned by our model so that the two subjects share the same baseline
characteristics (i.e., they are twins). Because the model is probabilisitic, the two twins have different
outcomes even though they share the same starting characteristics.
4
II. METHODS
A. Generating Digital Subjects with a Conditional Restricted Boltzmann Machine
Clinical data have many properties that make statistical modeling challenging. Data
can come in varied modalities such as binary, ordinal, categorical, and continuous. Fur-
thermore, observations may be occasionally or frequently missing. Conditional Restricted
Boltzmann Machines (CRBMs) are well suited to address these challenges, and in past work
we have found that CRBMs are able to effectively model disease progression in Alzheimer’s
Disease [2].
A CRBM1 is a class of probabilistic neural network that learns a joint probability distri-
bution over time, and is closely related to Restricted Boltzmann Machines [26–30]. A CRBM
learns the relationship between covariates at K visits expressed as a parametric probability
distribution. For example, for K = 3 with a 3-month spacing between visits the distribution
takes the form
p(x(t+ 3),x(t),x(t− 3)) = Z−1
∫
dh e−U(x(t+3),x(t),x(t−3),h) , (1)
in which x(t) is the vector of covariates at time t (in months), h is a vector of hidden
variables, U(·) is called the energy function, and Z is a normalization constant. More
details are provided in the Supporting Information.
The CRBM allows for approximate sampling from the joint probability distribution over
all covariates and across K visits. Thinking of disease progression as a Markov process,
the model can be used to probabilistically generate data for a subject at a visit given data
from the previous K − 1 visits. For MS, we model data in 3-month intervals and find that
modeling K = 3 simultaneous visits in the CRBM is sufficient to accurately generate long
trajectories. In other words, we model MS clinical trajectories as a lag-2 Markov process.
The CRBM is used in an iterative fashion to generate clinical trajectories for digital
subjects or digital twins. To generate a digital subject, the model is used to generate data
at time zero (i.e., at baseline) by sampling from p(x(t = 0)) using Markov Chain Monte Carlo
(MCMC) methods. To generate a digital twin, the covariates at time zero (baseline) are set
1 We use a version of CRBMs that have purely undirected connections, for which only a composite likelihood
may be used for training, that is more appropriate for this application; see the Supporting Information
for discussion.
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equal to the observed covariates of a particular patient. Starting from these baseline data,
the CRBM is used to generate data for the 3- and 6-month visits for that subject by sampling
from p(x(t = 6),x(t = 3)|x(t = 0)). Then these sampled 3- and 6-month visit data may be
used to generate data for the 9-month visit by sampling from p(x(t = 9)|x(t = 6),x(t = 3)).
Similarly the sampled 6- and 9-month visit data may be used to generate data for the 12-
month visit by sampling from p(x(t = 12)|x(t = 9),x(t = 6)). This continues as needed to
create clinical trajectories of the desired length.
Under this framework, we can now define digital subjects and digital twins more formally.
A digital subject is a clinical trajectory of length τ sampled from the joint distribution across
all τ visits {x(t)}t=τt=0 ∼ p(x(t = τ), . . . ,x(t = 0)). A digital twin is a clinical trajectory
of length τ in which the visits after t = 0 are sampled from the conditional distribution
{x(t)}t=τt=3 ∼ p(x(t = τ), . . . ,x(t = 3)|x(t = 0)).
One important concept is that digital subjects and digital twins are stochastic. Therefore,
one can create many digital twins for a given patient. Each of these digital twins will have
the same covariates at baseline, but their trajectories will differ after t = 0. Taken together,
these digital twins map out the distribution of possible clinical trajectories for that patient.
Note that subjects in clinical trials do not receive different treatments at the baseline visit,
so that digital twins may be created for subjects in any arm. If the CRBM models the
progression of the disease under the control condition, then the model may be used to
generate counterfactuals that can be used to estimate treatment effects. In this work, our
training and validation data were collected entirely from placebo control arms of previously
completed clinical trials so that digital subjects generated from the model are representative
of placebo controls.
A schematic overview of our process for building the CRBM and generating digital twins
is given in Figure 2.
B. Data
One legacy of the long history of clinical development for MS is a rich set of historical
clinical trials with placebo arms. The Multiple Sclerosis Outcome Assessments Consortium
(MSOAC) [8] has compiled data from 16 clinical trials that span three subtypes of MS: re-
lapsing remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS).
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FIG. 2. Overview. A graphical summary of the process used to build the CRBM studied in this
paper (A), and how digital twins are analyzed (B). To build the model, MSOAC data in SDTM
format are converted to a numerical form suitable for machine learning. A set of models are trained
that sweep over a grid of hyperparameters, variations in the way the model is trained. The final
model is selected by computing metrics on validation data and choosing the best ranked model.
An important feature of the CRBM is that it can create digital subjects and digital twins. Digital
subjects are synthetic clinical records generated from the model. Digital twins are digital subjects
whose baseline data is that of a given subject, allowing for subject-level predictions of outcomes.
The CRBM is probabilistic, meaning many digital twins may be created for an actual subject and
used to build distributions of predicted outcomes. In this work we use digital twins to analyze the
quality of the CRBM as a disease progression model.
A database of placebo arms from 8 of these trials comprising 2465 subjects has been made
available to qualified researchers. This database contains measurements spanning a number
of domains including background information, questionnaires and functional assessments,
medical history, and concomitant medications. No imaging or biomarker data is available.
MSOAC data are encoded according to the Study Data Tabulation Model (SDTM) for-
mat, a highly structured format commonly used to submit the results of clinical trials to
regulatory authorities [31, 32]. Starting from the MSOAC placebo dataset, we standard-
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Name Category Type Longitudinal Statistics Missing [%]
Baseline Age Background Continuous No 42 (10) [years] 1
Sex Background Binary No 67% female 0
Race Background Binary No 91% white 33
Region Background Categorical No 64% Europe 58
MS type Clinical Categorical No 65% RRMS 0
# of relapses, 1 year before baseline Clinical Ordinal No 1.4 (0.8) 26
# of relapses, 2 years before baseline Clinical Ordinal No 2.2 (1.3) 68
Relapse events Clinical Binary Yes 95% no-relapse 0
KFSS bowel and bladder system Clinical Ordinal Yes 0.83 (0.98) 13
KFSS brain stem system Clinical Ordinal Yes 0.64 (0.87) 13
KFSS cerebellar system Clinical Ordinal Yes 1.27 (1.17) 14
KFSS mental system Clinical Ordinal Yes 0.58 (0.84) 13
KFSS pyramidal system Clinical Ordinal Yes 1.86 (1.16) 13
KFSS sensory system Clinical Ordinal Yes 1.19 (1.11) 13
KFSS visual system Clinical Ordinal Yes 0.76 (1.00) 13
Ambulation EDSS component Clinical Ordinal Yes 0.72 (1.36) 1
Timed 25-Foot Walk Functional Continuous Yes 9.5 (14.6) [s] 1
Nine-Hole Peg, dominant hand Functional Continuous Yes 24.8 (15.2) [s] 1
Nine-hole Peg, non-dominant hand Functional Continuous Yes 27.7 (22.7) [s] 1
Paced Auditory Serial Addition Test (3s) Functional Continuous Yes 47.4 (11.8) 1
TABLE I. Covariates used in the model are grouped into three categories: background, clinical,
and functional. Background covariates are demographics that characterize the subject population.
Functional covariates assess various aspects of MS-induced disability such as ambulation, motor
skills, and cognitive function. Clinical covariates describe a subject’s clinical state such as the type
of MS, degree of disability (through the Kurtzke Functional Systems Score, or KFSS, components),
and relapse information. The Statistics column gives the mean and standard deviation of each
covariate (or the dominant category for binary or categorical variables) at baseline in the combined
training, validation, and test sets. The Missing column gives the percentage of missing data for
each covariate at baseline.
ized and converted SDTM-formatted measurements into a tidy format [33] more suitable for
statistical analysis and machine learning as described in the Supporting Information.
Twenty different covariates, described in Table I, were selected for inclusion in the model
due to their clinical relevance and presence (non-missingness) in the dataset. They princi-
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pally span background, clinical, and functional domains. Other clinically useful variables,
such as questionnaires with data recorded for only a small fraction of subjects, were ex-
cluded. The components of EDSS and relapse events, the primary non-imaging endpoints
in clinical trials, were included in the covariates modeled. Additionally, we added a simple
longitudinal covariate that is modeled as binary, which is 1 at baseline and 0 otherwise. This
allows the model to treat baseline as a special time.
Each selected covariate was classified as either longitudinal or static and as one of binary,
ordinal, categorical, or continuous; these classifications affect how the covariate is modeled
by the CRBM. The resulting dataset contains clinical trajectories for all subjects in the
database in 3-month intervals for up to 48 months and an average duration of approximately
24 months.
Most subjects have a 3-month visit interval, but a 6-month interval is also present for
approximately 800 subjects. Visit days were standardized to have a baseline visit day of
0, and longitudinal measurements were grouped into windows centered on each 90-day (3-
month) visit and averaged. Any visit windows without a measurement for a particular
covariate were recorded as missing.
We model each of the constituent components of the EDSS score, a combination of the
7-component Kurtzke Functional Systems Score (KFSS) assessment of function in a variety
of body systems [13, 34, 35] and the ambulatory function of the subject. We discuss the
advantages and methods around different approaches for representing these data more in
the Supporting Information.
Before training, we removed 70 subjects that had essentially no data beyond baseline,
resulting in a dataset with 2395 subjects. This dataset was divided into mutually exclusive
training (50% of the data, or 1198 subjects), validation (20% of the data, or 479 subjects),
and test (30% of the data, or 718 subjects) datasets. Due to the computational cost of
associated with our training procedure, we had to rely on a single train-validation-test split,
as opposed to a method like k-fold cross validation.
C. Training
A well-trained CRBM is able to generate digital subjects with the same statistical prop-
erties as actual subjects in the dataset. To accomplish this goal, we trained the CRBM via
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stochastic gradient ascent to maximize a convex combination of a composite likelihood and
an adversarial objective as previously described [2, 10]. The relative weight given to the
likelihood and adversarial components of the objective function was treated as a hyperpa-
rameter.
Hyperparameters refer to various parameters of the model or training process that must
be specified, but cannot be learned by applying gradient ascent to the objective function
as with the main model parameters. These hyperparameters included the weighting of
the likelihood and adversarial terms of the objective function, number of epochs, batch
size, initial learning rate, number of hidden units, magnitude of parameter regularization,
and sampling parameters (i.e., the number of Monte Carlo steps and the magnitude of
temperature-driven sampling [10]). We performed a grid search over each of these dimensions
in parallel, training a total of 1296 CRBMs with various hyperparameter choices to maximize
an objective function on the training dataset.
After training the CRBMs in the grid search, we evaluated them using a variety of metrics
that assess a model’s statistical performance as well as clinically important outcomes. All
metrics were computed on the validation dataset. The statistical metrics are coefficients of
determination (R2 values) between the actual subjects from the test set and their digital
twins the for equal-time and lagged autocorrelations. Three clinical metrics were used, one
measuring the ability to predict individual relapse events, another measuring the agreement
between average EDSS progression values for the data and model, and the third measuring
the agreement between chronic disease worsening (CDW) fractions for the data and model.
We adopted a minimax approach to choose a best performing model across the grid
search. That is, we aimed to choose a CRBM that performed well across all metrics, even if
it was not the best performing model on any single metric. To accomplish this, we ranked all
N (N=1296) models from best (rank 1) to worst (rank N) for each metric and determined
the worst rank across metrics for each model. We used this worst rank to choose the top
25% of models. This selected models that performed well on all metrics. To choose a best
model from this set, we repeated the process on the clinical metrics alone, ranking models
on the clinical metrics and determining the worst rank of each model. We selected the model
with the lowest (best) worst rank and designated this as the “optimal” model. Narrowing
the focus to the clinical metrics emphasized their importance in model selection.
The hyperparameters of this optimal model were then used to train a new, “final” model
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on the combined training and validation datasets. All results that follow in the main text
focus on the performance of this final model computed using the test dataset. More details
on the hyperparameters, training procedures, and selection process for the optimal model
are described in the Supporting Information.
III. RESULTS
A. Model Performance Across the Hyperparameter Sweep
The hyperparameter sweep trained 1296 models over a grid of hyperparameters on the
training dataset. 83 of these models failed to finish training due to poor performance (e.g.,
due to too high of a learning rate), and were excluded from further evaluation because they
were ranked lowest in model selection. We computed the model selection metrics using
the validation dataset on the remaining 1213 models and determined the hyperparameters
of the optimal model. These hyperparameters were used to train a new model on the
combination of the training and validation datasets, which we refer to as “the final model”.
For comparison, the test metrics were computed using both the optimal model determined
from the validation set and the final model trained on combining training and validation
sets.
The distributions of the validation metrics used for the hyperparameter sweep are shown
in Figure 3, along with metric values for the optimal and final models. As expected, the
optimal model performed well on all metrics without performing poorly on any individual
metric. Furthermore, the performance of the optimal model was consistent across the vali-
dation and test datasets, with the largest the CDW fraction showing the largest difference.
The performance of the optimal and final models on the test dataset were also quite similar,
aside from the relapse prediction metric. This suggests that overall model performance is
fairly stable with respect to changes to the dataset used for model training or evaluation.
B. Assessing Statistical Indistinguishability of Digital Twins
We say that digital twins and actual subjects are statistically indistinguishable if statis-
tical analysis methods cannot differentiate the two groups better than random chance. Due
11
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FIG. 3. Metrics used to select hyperparameters for the best performing model. For
each metric used, the distribution of values across the hyperparameter sweep determined using the
validation dataset is shown (gray histogram). The best performing model that was selected from
this set is shown as a dashed black line at its value for each metric. The dashed blue line shows
the value of the metric for this best performing model, computed on the test dataset. The solid
blue line shows the value of the metric for the final model, computed on the test dataset. For each
metric, an arrow indicates whether smaller or larger values are better.
to the complexity of clinical data, there are a number of ways to assess statistical indis-
tinguishability. We focus on three different methods to quantitatively assess the degree of
indistinguishability that span from subject- and covariate-level statistics to population-level
statistics. The first compares the means, standard deviations, correlations, and autocorre-
lations of all covariates computed from the digital twins to those computed from the actual
subjects, quantifying agreement using linear regression and coefficients of determination
where appropriate. The second aims to quantify the agreement between the observed clin-
ical trajectory of a particular patient and the distribution of potential clinical trajectories
defined by his/her digital twins. The third trains logistic regression models to distinguish
between actual subjects and their digital twins, quantifying performance with the area under
the receiver operating characteristic curve (AUC).
To evaluate the statistical indistinguishability of digital twins, we created 1000 digital
twins for each of the 718 actual subjects in the test dataset. The statistical properties
of these twins were compared to the actual subjects in a number of ways to quantify the
goodness-of-fit of the CRBM.
First, in Figure 4 we compare the means, standard deviations, correlations, and autocor-
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FIG. 4. The model captures the leading statistical moments of the data. Moments for the
actual subject data are plotted against moments for digital twins for means, standard deviations,
equal-time correlations, and lagged autocorrelations. Each digital twin contributes data for the
same study duration as its actual subject counterpart up to 36 months. The means and standard
deviations are compared at each visit, with a logarithmic scale used to accommodate differing
scales of the covariates. For the equal-time and lagged autocorrelations the correlation coefficient
is computed for each pair of covariates across all visits. In all cases the slope and intercept fit
coefficients shown come from regressions weighted by the fraction of data present for each covariate.
Points on the plot are darker if more data is present (see the color bar). These regressions estimate
the relationship between actual subjects and digital twins. Theil-Sen regression is used for the
means and standard deviations, which is outlier robust and appropriate for the widely varying
scales present [36, 37]. For the equal-time and lagged autocorrelations, an ordinary least squares
regression is used, which allows the R2 values shown to be computed. The best fit line is shown for
each comparison.
relations between covariates computed from the actual subjects and a cohort consisting of
a single digital twin for each subject. The duration of the clinical trajectory of each digital
twin was the same as the matched patient. We ignored the baseline time point when com-
13
Ti
m
ed
 2
5-
Fo
ot
 W
al
k
9-
H
ol
e 
Pe
g 
(D
om
in
an
t)
9-
H
ol
e 
Pe
g 
(N
on
-D
om
in
an
t)
PA
SA
T 
(3
-S
ec
on
d)
K
FS
S 
Py
ra
m
id
al
K
FS
S 
Se
ns
or
y
K
FS
S 
B
ow
el
 B
la
dd
er
K
FS
S 
Vi
su
al
K
FS
S 
C
er
eb
el
la
r
K
FS
S 
B
ra
in
 S
te
m
K
FS
S 
M
en
ta
l
Am
bu
la
tio
n 
Sc
or
e
1
0
1
time
p < 0.05 (multiple testing)
m
od
el
 u
nb
ia
se
d
m
od
el
 m
ea
n
bi
as
ed
m
od
el
 v
ar
ia
nc
e
to
o 
sm
al
l
m
od
el
 v
ar
ia
nc
e
to
o 
la
rg
e
examples
FIG. 5. The model accurately simulates individual subject trajectories. The mean and
standard deviation of a statistic measuring subject-level agreement of the data with the CRBM,
for each longitudinal covariate. Each visit beyond baseline is displayed using a point for the mean
and an error bar for the standard deviation. The visits are ordered for each covariate, with data
shown up to 36 months. For each subject, a p-value for each covariate at each visit is computed
by comparing the data value to the distribution of values predicted by the CRBM under repeated
simulations of digital twins for that subject. The inverse normal CDF is applied to this p-value to
define a statistic, ϕ ≡ Φ−1(p), and the mean and standard deviation of the distribution of ϕ over
subjects are computed and plotted as a point and error bar. As the diagram on the left explains,
if the CRBM is in statistical agreement with the data (unbiased) then the mean should be 0 and
the standard deviation should be 1. Different types of bias are shown, and we label statistically
significant cases (p < 0.05, with a confidence level adjusted to 0.05/144 after applying a Bonferroni
correction that factors in the 144 comparisons shown in the figure) in red.
puting the statistics because the actual subject and his/her digital twin have the same values
of all covariates at the initial time point, by definition. All of the statistics computed from
the cohort of digital twins agree with those computed from the cohort of actual subjects,
with R2 values for all comparisons greater than 0.95 and best fit coefficients close to their
ideal values (i.e., 0 for the intercept, 1 for the slope).
Figure 4 compares a cohort of actual subjects to a cohort of matched digital twins based on
population-level statistics. It is also important to quantify performance using statistics that
are sensitive to subject-level agreement between an actual subject and his/her digital twins
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as in Figure 5. We generated 1000 digital twins for each actual subject. For each subject,
each covariate, and each visit, the samples from the digital twins form a distribution to which
the observed data for the actual subject may be compared. We used the distribution defined
by the digital twins to compute a tail area probability (i.e., p-value) for each observation,
then used the inverse cumulative distribution function of the standard normal distribution
to convert the p-value to a statistic, ϕ = Φ−1(p), that has mean 0 and standard deviation
1 if the digital twins and subject data are drawn from identical distributions. This statistic
controls for highly non-normal distributions of covariates better than a traditional z-score.
We applied the Kolmogorov-Smirnov test to assess the if the distribution of these statistics
is not N (0, 1) and mark any cases with statistically significant disagreement at α = 0.05
after a Bonferroni correction.
Only early visits for the timed 25-foot walk and 9-hole peg test show statistically signif-
icant differences between actual subjects their digital twins, with the difference primarily
due to the standard deviation of the ϕ distribution being too small. This indicates that the
standard deviations of the distributions defined for these covariates by the digital twins are
too large. These two functional tests are scored as time to completion of a task. Subjects
can have large single-visit outliers in this time due to short-term ambulatory or motor diffi-
culties, which is particularly challenging to learn. Although the model generally agrees with
the data well, these results suggest that the CRBM generates large times for these tests too
frequently.
Finally, in Figure 6, we demonstrate that a logistic regression model cannot distinguish
between an actual subject and one of his/her digital twins better than random chance,
which is a direct evaluation of statistical indistinguishability. For each time point (except
baseline, when the actual subjects and their twins are the same by definition), we trained
a logistic regression model to distinguish between each subject and his/her digital twins.
In addition, we trained logistic regression models to distinguish between each subject and
his/her digital twins using differences between time points. Over 36 months, nearly every
logistic regression model’s performance is consistent with random guessing, meaning they
are unable to distinguish between actual subjects and their digital twins better than random
chance.
15
3 6 9 12 15 18 21 24 27 30 33 36
Time [months]
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Lo
gi
st
ic
 R
eg
re
ss
io
n 
AU
C
statistically
indistinguishable
ba
se
lin
e
3 6 9
logistic regression
models
single visits
visit changes
FIG. 6. Digital twins are challenging to distinguish from actual subjects. The area
under the receiver operating characteristic curve (AUC) of logistic regression models trained to
distinguish between actual data and their digital twins are shown. An AUC of 0.5 indicates the
logistic regression model cannot differentiate between actual data and their digital twins better
than random chance, while an AUC of 1 indicates the model can perfectly differentiate between the
two groups. As the diagram at left shows, at each visit beyond baseline we evaluate the ability to
distinguish digital twins from data either on data from a single visit (black circles) or the change in
data from one visit to the next (orange triangles). In each case the point shown is the mean AUC
is taken over 100 different simulations with different digital twins for each simulation; the error
bars on the points show the standard deviation over simulations. The AUC for each simulation is
estimated using 5-fold cross validation. Missing data from actual subjects is mean imputed; the
corresponding values for the digital twins are assigned the same mean values to avoid biasing the
logistic regression models.
IV. DISCUSSION
This work introduced three terms: digital subjects, digital twins, and the concept that
digital subjects may be statistically indistinguishable from actual subjects. Using a dataset
of subjects enrolled in the placebo arms of MS clinical trials, we trained a Conditional Re-
stricted Boltzmann Machine to generate digital subjects. This dataset included demographic
information and disease history, functional assessments, and components of the EDSS score.
The model learned the relationship between covariates across multiple visits, treating dis-
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ease progression as a Markov process; this means that given data for a subject at some
number of prior visits, the model is capable of generating clinical trajectories representing
the distribution of potential outcomes at future visits for that subject. Using a variety of
statistical tests, we demonstrated digital subjects generated by the CRBM are statistically
indistinguishable from actual subjects enrolled in the placebo arms of clinical trials for MS.
Modeling MS disease progression is challenging due to the complexity of endpoint mea-
sures and the varied course of the disease. Relapses are difficult to predict, and the EDSS
score has multiple domains and depends on many components. It’s likely that significant
improvements could be made to our model by incorporating additional data on imaging-
related endpoints is important as these endpoints are commonly studied in clinical trials,
laboratory tests, and adverse events. Incorporating these additional covariates would enable
generation of digital subjects with most of the covariates that are typically measured in
MS clinical trials. In addition, incorporating data from subjects treated with interferons or
other commonly-used DMTs would make it possible to generate cohorts of digital subjects
representing broader control populations.
The ability to generate digital twins that are statistically indistinguishable from actual
subjects enrolled in control arms of clinical trials is a powerful tool to understand disease
progression and model clinical trials. Each digital twin represents a potential outcome of
their matched patient; that is, what would likely happen to this patient if she/he were
to receive a placebo in the context of a clinical trial? Models of potential outcomes are
important tools for estimating treatment effects [38–40], and ability to generate digital twins
representing per-subject controls opens the door to a variety of novel clinical trial analyses
aimed at assessing responses to treatments for individual patients.
Taken in-context with previous work by the authors applying CRBMs to generate digital
subjects for Alzheimer’s Disease [2], this work suggests that approaches based on probabilis-
tic neural networks like CRBMs will be broadly applicable to generating digital subjects
across multiple diseases.
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Appendix A: Data Processing and Datasets
Data from the MSOAC database is stored in Study Data Tabulation Model (SDTM)
format. The transformation of data from SDTM formation to a format useful for statistical
analysis and machine learning requires many steps. The MSOAC database, which aggregates
data from multiple clinical trials in SDTM format, is a clean and high-quality data source.
Because source data in the MSOAC database are from different clinical trials, particular
attention must be paid to harmonization, to ensure that data for the same concept are
represented the same way. This can easily happen, for example, if different trials use different
conventions to encode measurements.
Besides harmonization, data must be converted from SDTM format to a data format that
is suitable for analysis. SDTM represents observations in terms of variables encoding broad
contextual data about the observation, while statistical analyses use tabular formats where
covariates come with implicit definitions and values for covariates are plain data types. This
tabular format is well described by the tidy data concept [33].
To carry out data processing, we have built a software library in python that makes it
easier to harmonize data, convert between formats, and document and test the steps taken.
This toolkit is described in [2], and has proven effective here.
1. Covariates Used in Training
111 covariates were extracted from the MSOAC database using the processing methods
described above, from which we selected a subset of 20 covariates relevant to modeling MS
progression that are without substantially missing data or are relevant for clinical trials.
We note that many covariates not included in the model describe components of question-
naires rarely measured (43 covariates from SF-12, BDI-II, and RAND-36), characterization
of disability in medical history (20 covariates), or medication data that lacked dosing time
information (16 covariates).
Although subjects were part of placebo control arms, they may have been taking medi-
cations that are part of the standard of care for treating MS or other conditions. Some of
these medications, such as those considered to be disease modifying, are known to influence
the evolution or presentation of MS. DMT medications were rarely used (5% of subjects
21
received them) and were likely provided as rescue therapies from relapses or adverse events.
However, as dosing time information was not provided, these variables were not included in
dataset.
The processing of components of the EDSS score merit discussion. The EDSS score is
especially challenging to model. The lower range of EDSS is defined by a complex scor-
ing function applied to the components of the Kurtzke Functional Systems Score (KFSS)
components, a 7-component test assessing function in variety of bodily systems [13, 34, 35].
The upper range of EDSS is principally defined by the subject’s ability to walk. Due to the
nature of scoring, some values are much more likely than others, giving a very multi-modal
marginal distribution of EDSS scores. We chose to model the individual KFSS components
and ambulatory impairment of subjects rather than model the total score directly, allowing
the model to learn the simpler constitutive covariates and the relationships between them.
Unfortunately, the MSOAC database does not record the ambulatory impairment com-
ponent of EDSS directly. Instead, we infer this ambulation score from the EDSS score and
encode it as an ordinal covariate. The covariate is determined by the number of 0.5-units
the reported EDSS score is above the ambulation cutoff (4.5); cases where the EDSS score
is equal to or smaller than the ambulation cutoff yield an ambulation score of 0. Note that
we are assuming that subjects with high KFSS scores have impaired ambulatory function.
KFSS scoring rubrics do not provide consistent guidelines for assigning scores above the
ambulation cutoff, indicating this assumption is valid.
As a cross-check, we are able to compute the EDSS score from the KFSS components
alone. When the EDSS score was outside of the ambulatory range, we were able to compare
the reported EDSS score with the value given by the KFSS components. In approximately
10% of cases we found a disagreement, and in a majority of these cases we were able to
clearly identify an apparent mis-scoring of EDSS based on the reported KFSS component
scores.
When training the CRBM, performance is improved the scale of each covariate is similar.
Therefore, we apply a normalizing transformation to most covariates to ensure the range of
each covariate is of order 1. For binary and categorical covariates no normalization is applied,
while for ordinal covariates we scale the covariate by its maximum so that the values range
between 0 and 1. For continuous covariates we apply different normalizing transformations
depending on the features of the covariate. In Table II we give these transformations along
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Name Encoding Domain Normalizing Transformation
Baseline Age Continuous 18− 72 Standardization
Sex Binary {0, 1} None
Race Binary {0, 1} None
Region 1-hot, 3 labels {0, 1} None
Baseline Binary {0, 1} None
MS type 1-hot, 3 labels {0, 1} None
# of relapses, 1 year before baseline Ordinal {0, 1, . . . , 7} Scaled by 1/7
# of relapses, 2 years before baseline Ordinal {0, 1, . . . , 14} Scaled by 1/14
Relapse events Binary {0, 1} None
KFSS bowel and bladder system Ordinal {0, 1, . . . , 6} Scaled by 1/6
KFSS brain stem system Ordinal {0, 1, . . . , 5} Scaled by 1/5
KFSS cerebellar system Ordinal {0, 1, . . . , 5} Scaled by 1/5
KFSS mental system Ordinal {0, 1, . . . , 5} Scaled by 1/5
KFSS pyramidal system Ordinal {0, 1, . . . , 6} Scaled by 1/6
KFSS sensory system Ordinal {0, 1, . . . , 6} Scaled by 1/6
KFSS visual system Ordinal {0, 1, . . . , 6} Scaled by 1/6
Ambulation component of EDSS score Ordinal {0, 1, . . . , 11} Scaled by 1/11
Timed 25-Foot Walk Continuous 2− 300 Logit scaled to range
Nine-Hole Peg, dominant hand Continuous 10− 260 Logit scaled to range
Nine-hole Peg, non-dominant hand Continuous 10− 260 Logit scaled to range
Paced Auditory Serial Addition Test Continuous 0− 60 Logit scaled to range
TABLE II. Covariates used in the model, their domain, encoding, and the normalizing transforma-
tion applied to them. Categorical covariates (which are 1-hot encoded) and binary covariates have
no normalizing transformation, while ordinal covariates are scaled to have a maximum value of 1.
Continuous variables are normalized in different ways, but each results in a range where values are
not much larger than 1.
with the encoding and its natural range.
For age, the “standardization” transform means we subtract the mean and divide by
the standard deviation, where both moments are determined from the training set. The
functional assessment covariates (timed 25-foot walk, 9-hole peg test, and paced auditory
serial addition test (PASAT)) all use a logit transformation. The functional form of these
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transformations is
x˜ = log
(
x− (x− + δ)
(x+ + δ)− x
)
, (A1)
where x± are upper and lower limits of the covariate (the range values given in the table)
and δ is a buffer to prevent the argument from being to small or large (we use δ = 0.5).
This transformation, like the others used, are invertible, meaning we can transform from the
representation of the data generated by the CRBM to retrieve the natural representation of
the data. For the PASAT test, we choose to model the covariate as continuous (rounding the
value when using the model output) rather than ordinal due to the large number of possible
values.
Appendix B: CRBMs
1. Summary of CRBMs
Restricted Boltzmann machines (RBMs) [26, 29] are a well-known class of probabilistic
neural networks capable of representing the complex interrelationships between variables
in large datasets. They provide several features critical to modeling clinical data (see the
supplementary material in [2]).
A Conditional Restricted Boltzmann Machine(CRBM) is a type of probabilistic model
that provides a way to model time series data by leveraging the natural capabilities of
Boltzmann machines. In fact a CRBM is an RBM in which the organization of the visible
units is particular to the time-dependence of the data. That is, without particular temporal
labels on the visible units of the CRBM, the model is simply an RBM. These models can
be trained the same way as RBMs, except that the temporal nature of the data potentially
requires a reorganization of the training data.
In the original development [12, 41], CRBMs are defined as a particular kind of graph-
ical model encompassing an RBM whose probability distribution depends conditionally on
previous time points.
That is,
p(xt+k|xt+k−1, . . . ,xt) = Z−1
∫
dh e−U(xt+k,h|xt+k−1...,xt+1,xt) , (B1)
in which xt is the vector of covariates at time index t, h is a vector of hidden variables, Z is
a normalization constant, and U(·|·) is the conditional energy function. Here the conditional
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energy function is a family of functions parametrized by linear functions of the previous time
points. Graphically, this is a graphical model in which there are directed arrows extending
from the previous time points to the hidden units of an RBM.
In our incarnation we have generalized the definition slightly in two regards. First, we
allow some sector of the visible variables to be time-independent (denoted xstatic). Secondly
we modify the model graph so that it admits exclusively undirected arrows. We can recover
the original notion of a CRBM by simply conditioning on the prior time points’ visible units.
Specifically, the joint probability distribution of k + 1 time-adjacent vectors
p(xt+k, . . . ,xt+1,xt,xstatic) = Z−1
∫
dh e−U(xt+k,...,xt+1,xt,xstatic,h) , (B2)
in which the energy function U(·) takes the form,
U(xt+k, . . . ,xt+1,xt,xstatic,h) =
∑
i=0,1,...,k,static
[∑
j
ai,j(xt+i,j)+
∑
jµ
Wi,jµ
xt+i,j
σ2i,j
hµ
2µ
]
+
∑
µ
bµ(hµ) .
(B3)
Each unit of the visible and hidden layers has bias parameters determined by the choice
of functions aij(·) and bµ(·), as well as scale parameters σij and µ. The connection between
the layers is parameterized by the weight matrices Wi,jν .
Understood as a single RBM, our CRBM contains the visible units for multiple time
points, with a standard hidden layer. The visible units are organized as:
xCRBM = xt+k ⊕ xt+k−1 ⊕ · · · ⊕ xt ⊕ xstatic , (B4)
where k is the time lag of the model and ⊕ signifies concatenation. The static units are
only used once over all time points, as they are constant over all times. The model learns
the complete joint probability distribution between all k+1 adjacent time points simultane-
ously, p(xt+k, . . . ,xt,xstatic). That means that any conditional sampling of the data may be
performed, such as predicting the data for a time point given the previous k time points. A
baseline cohort may be simulated by sampling from the model and using the first time point.
This treatment of the data to allow for learning inter-dependence between time points is
the only distinction of a CRBM over a standard RBM. In Figure 7, we show a schematic
diagram highlighting the differences between an RBM, the CRBM we describe here, and the
CRBM originally described in [12, 41].
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FIG. 7. Architectures of RBMs and CRBMs. A schematic architecture of the CRBM used in
this work is shown in the middle, compared to an RBM, which is an equivalent architecture, and
the original CRBMs, which are described in the text. Both the RBM and CRBM used here have
completely undirected connections, while the original CRBM has directed connections except for
the last time point. Directed connections are shown as gray arrows.
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2. Training methods
The CRBM is trained on the data from adjacent triples of time points. If xt is the vector
of time-dependent variables for a patient at time t (in months) and xstatic is the vector of
static variables for the same patient, then the visible units used to train the CRBM are
v = {xt+6,xt+3,xt,xstatic}, a concatenation of the data from the adjacent time points t, and
t+ 3 months, and t+ 6 months with the static variables represented only once.
As discussed in the main text, to train the CRBM we divided the 2395 subjects in the
dataset up into 3 parts: training (50% of subjects), validation (20% of subjects), and test
(30% of subjects). Training was done in two stages. First we train a large number (1296)
models over a grid of hyperparameters and measure the performance of models according to
a number of metrics. The hyperparameters of the best-performing model were used to train
a model on the combination of the training and validation data.
To train the model, we take data from a subject’s trajectory and transform it to the
format used by the model. This involves 3 steps:
1. For each subject we create vectors of data from all possible sets of 3 consecutive visits.
For example if a subject has data through 12 months we create vectors for 0, 3, and
6 months, 3, 6, and 9 months, and 6, 9, and 12 months. Repeated occurrences of the
static (non-longitudinal) covariates are dropped so that they only appear once in the
vector.
2. Frequently subjects may be missing data. If any vector has no longitudinal data for
the last visit, it is removed. This removes certain vectors in cases where the subject
has missed visits.
3. We standardize the data by transforming covariates so that their range is of order 1.
These are the transformations discussed in Section A.
Note that because each subject typically has trajectories much longer than the 6-month time
window (trajectories up to 57 months are used), the number of samples in the combined
training and validation datasets (11129) is much larger than the number of subjects. When
training, samples are all shuffled so that minibatches contain a mixture of subjects and
times.
27
The CRBM has a single hidden layer of ReLU units [42], and is trained using stochastic
gradient descent according to the setup of [10]. The objective C is a linear combination of
log-likelihood L and adversarial A objectives,
C = −γL − (1− γ)A , (B5)
in which γ is a parameter weighing the relative size of the two objectives. Here we use a
random forest classifier for the adversary. The parameter γ is one of the hyperparameters
selected via a grid sweep.
It is important to note that the likelihood L is the likelihood of observing a given three-
timepoint trajectory according to the model’s distribution. It is not the likelihood of observ-
ing an arbitrary-length trajectory generated by the model via conditional sampling. In this
regard the the model minizes a partial likelihood with respect to arbitrary length trajectories.
3. Temperature driven sampling
An important concept for stochastic models is the notion of mixing, which contributes to
the ability of the model to simultaneously represent multiple different groups in the dataset.
A model with poor mixing cannot, for example, represent multiple subtypes of MS well
or effectively learn multiple modes of disease progression. To address this, we employ a
simple approach to improve the mixing of the CRBM when generating digital subjects or
digital twins. The underlying RBM that the CRBM is built upon can integrate the concept
of temperature, which enters the joint probability distribution as p(v,h) = Z−1e−βE(v,h),
where β is the inverse temperature and v and h are the visible and hidden units of the
model. By drawing the inverse temperature from an autoregressive gamma process [43]
with mean 1, a small standard deviation, and a non-zero autocorrelation, we can improve
the rate of mixing [10]. When β is small, mixing is fast and different modalities can be
explored and more efficiently learned. Setting the mean of β to 1 ensures that the samples
stay close to the true distribution, and when sampling we anneal the standard deviation of
β to 0 with no autocorrelation to ensure that the end of the Markov chain samples from the
true distribution. While training, we do not anneal and use an autocorrelation close to 1
(0.9) to ensure that the inverse temperatures evolve slowly and the system can remain near
equilibrium. Unlike parallel tempering [44, 45], this algorithm for driven sampling does not
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sample from the exact distribution, and instead samples from a similar distribution to the
RBM that has fatter tails. However, this approach adds only a small computation cost and
appears to improve training outcomes (in this and other applications); see [10] for details.
Appendix C: Hyperparameter Sweep and Model Selection
1. Hyperparameters
Multiple hyperparameters are used in training the CRBM. To select an optimal model,
we trained a set of models over a grid of these hyperparameters and chose the model that
performed the best on a set of metrics computed on the validation dataset. The grid, along
with the hyperparameters of the selected model are shown in Table III. The grid was chosen
to scan over reasonable ranges of key hyperparameters and fix others at reasonable values
that are not expected to significantly affect model performance. Note that the number of
samples in the combination of the training and validation datasets (11129) and the number
of visible units (53) are used in defining the hyperparameters for training the model. The
number of hidden units is set as a fraction of the number of visible units, and the batch size
is set as a fraction of the number of samples. In total, 1296 models were trained.
2. Selection Metrics
Because CRBMs are generative, model performance can be assessed in a number of
ways. This makes it challenging to find an optimal model across the hyperparameter grid,
as different models may be relatively better or worse given the evaluation method. We
addressed this by selecting models that performed well across a number of metrics.
We chose metrics in two categories: ones that assessed the statistical quality of samples
generated by the model, and ones that assessed clinical performance of the model. The
statistical metrics are the coefficients of correlation between equal-time and lagged autocor-
relations for the test dataset and digital twins of the validation dataset under the hypothesis
that the correlations are equal between actual data and digital twins. Each autocorrelation
contributes a weight to the coefficient of correlation proportional to the fraction of the test
dataset present. That is, if xdatat are covariates at visit t for the test dataset and xtwinst are
the same covariates for digital twins of subjects in the test dataset, then we compute the
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Hyperparameter Values
number of hidden units
⌈
1
2nvis
⌉
(27), nvis (53)
number of epochs 1250, 2500, 5000, 10000
batch size 557, 1113, 2226
initial learning rate 0.25/nvis, 0.5/nvis, 1/nvis
driven sampling σβ 0, 0.15, 0.3
`2 weight penalty 10−4, 10−3
adversary weight 0, 0.3, 0.7
Monte Carlo steps (sampling) 100
optimizer ADAM
TABLE III. The hyperparameter grid used to train the CRBM. The grid is defined as the Cartesian
product of the values listed across hyperparameters. The value of each hyperparameter for the
selected model is shown in bold. nvis is the number of visible units. The batch sizes are defined so
that there are 5, 10, or 20 batches per epoch in the combined training and validation datasets.
lag-` autocorrelations,
Cdata` = Cov[x
data
t ,x
data
t+` ] , (C1)
and equivalently for the digital twins. Taking cdata` as a vector of unique non-trivial entries
in Cdata` multiplied by the fraction of data that was not missing in the calculation of the
entries in Cdata` , the metric is
R2` = 1−
E[(ctwins` − cdata` )2]
E[(ctwins` − E[ctwins` ])2]
. (C2)
These coefficients of correlation are computed for ` = 0, 1, 2, 3 (` = 0 are the equal-time and
` > 0 are the lagged autocorrelations).
The clinical metrics focus on the EDSS and relapse endpoints. All metrics are computed
using 10 digital twins for each actual subject. They are:
• An absolute t-statistic for the CDW fraction in PPMS subjects. CDW is evaluated
for each subject in the test dataset and their digital twins, wdata and wtwins, and the
statistic is defined,
tCDW =
∣∣E[wdata −wtwins]∣∣
Var[wdata]1/2
√
n , (C3)
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where n is the number of PPMS subjects for which CDW can be computed. We use 3
particular definitions of CDW, each of which defines chronic worsening as an increase
of at least 1 point if the baseline EDSS is less than 6 and 0.5 otherwise, but vary in
the required period of sustained worsening and duration over which it is measured (6-
month sustained worsening over 1 year and 3-month and 6-month sustained worsening
over 2 years). We define the metric as the average of zCDW for these cases.
• An absolute t-statistic for the mean EDSS progression. The EDSS progression over
18 months is computed, sdata and stwins, and a metric is defined,
tEDSS =
∣∣E[sdata − stwins]∣∣
Var[sdata]1/2
√
n , (C4)
where n is the number of subjects for which the EDSS can be computed.
• The area under the receiver operating characteristic curve (AUC) that measures the
model’s ability to predict relapses beyond baseline, through 18 months. The metric is
the average AUC value for each visit from 3 to 18 months.
3. Model Selection
To identify the hyperparameters of the best performing model, the selection metrics
were computed for each model successfully trained in the hyperparameter grid. We adopt
a minimax approach to model selection, with the goal of selecting an optimal model that
performs well for all metrics rather than optimizing performance on a single metric. Model
selection comprises two steps:
1. For each metric, all N models are ranked from best performing (1) to worst performing
(N). The maximum rank (worst performing) over all metrics of each model is recorded.
The 25% of models with the lowest maximum rank are retained. This selects models
that perform well across all metrics, rather than models that rank well for individual
metrics and poorly in others.
2. For the surviving models, we re-rank the surviving models on each of the clinical
metrics alone. The model that has the lowest maximum rank over these metrics is
selected.
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The combination of these two steps ensures we obtain models that perform well across all
metrics and especially well on clinical metrics. The hyperparameters of the best performing
model are shown in bold in Table III. These hyperparameters are used to train a model on
the combination of the training and validation datasets.
Appendix D: Model Analysis
In this section we give quantitative details for the statistics shown in Figures 4, 5, and 6.
We define xdatat as the covariates at visit t for the test dataset and xtwinst as the same covariates
for digital twins of subjects in the test dataset.
In Figure 4 we compute several first and second order moments of test subjects and their
digital twins. These statistics are, for k = data and k = twins:
• Means for each covariate at each visit: µkt = E[xkt ].
• Standard deviations for each covariate at each visit: σkt = Var[xkt ]1/2.
• Equal-time and lagged autocorrelations taken over all times, Ck` = Cov[xkt ,xkt+`], for
` = 0, 1, 2, 3.
All moments are computed over the subjects in the test dataset. For each statistic, we
compute a regression between the values across covariates (or pairs of covariates) weighted
by the fraction of data present for each particular point. For the correlations, this requires
values for both covariates to be present for the statistic to be computed. For the means and
standard deviations, because the values for different covariates can have very different scales,
an ordinary least squares regression (and the corresponding coefficient of determination) is
outlier sensitive, so we use Theil-Sen regression. For the correlations, ordinary least squares
regression is sufficient, which allows us to report both the fit coefficients and the coefficient
of determination.
In Figure 5, we compute a statistic that quantifies the observed covariate values for a
given subject with the distributions predicted for that subject’s digital twins. As a start, for
any covariate value for a single subject at a single visit we compute a p-value of the under
the distribution of digital twins for that subject and visit:
pi,j,t(x
data
i ) = Φ
twins
i,j,t (x
data
i ) , (D1)
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where Φi,j,t is the empirical cumulative distribution function of digital twins for covariate
xi of subject j at visit t. If the CRBM learns the exact distribution of the data, then the
distribution of p-values should be uniform. One approach to testing statistical indistin-
guishability is to test the uniformity of this distribution using a 1-sample statistical test
such as Kolmogorov-Smirnov. While quite powerful, it is challenging to interpret what a
statistically significant result (a significant non-uniformity in the p-value distribution) means
for the CRBM other than a failure to model the data distribution well. Instead, we focus
on derived statistics that are much more interpretable.
From a p-value, we can compute a statistic from the inverse normal distribution,
ϕi,j,t = Φ
−1(pi,j,t) . (D2)
These values should be normally distributed across subjects, and the moments are especially
interpretable. If the mean is above (below) 0, then the mean of the model is lower (higher)
than the mean of the data. If the variance is smaller (larger) than 1, then the variance
of predictions of the model is larger (smaller) than the data. Note that the relationship
between the moments and the bias of the model is inverted due to the fact that the statistic
is comparing the data value to the model distribution. We plot the mean and standard
deviation of these ϕ values in Figure 5. To test significance, we combine the mean and vari-
ance into a single statistic by computing a 1-sample Kolmogorov-Smirnov statistic between
N (E[ϕi,j,t],Var[ϕi,j,t]) and N (0, 1), using n samples for the former distribution. The signif-
icant level of the Kolmogorov-Smirnov test is adjusted by a Bonferroni correction on the
number of test being performed, equal to the number of covariates evaluated (12) multiplied
by the number of time points (12), for a scaling factor of 144 (meaning a comparison is
significant if the p-value is less than 0.05/144).
In Figure 6, we compare the complete set of longitudinal covariates between test subjects
and their digital twins. We train a classifier model C to predict whether given covariate
values come from test subjects or their digital twins, and judge the performance of the
classifier using the area under the receiver operating characteristic curve (AUC). An AUC
score of 0.5 indicates that C cannot do better than random chance at determining whether
data comes from actual subjects or their digital twins, while an AUC of 1.0 indicates that
C can perfectly identify them. This is directly evaluating the statistical indistinguishability
of digital twins.
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The details of the comparison are as follows. Because different subjects can have different
durations, we make comparisons at single visits or the difference between consecutive visits
using all subjects still in their study at that visit (or pair of visits). Missing data is a
potentially large source of bias in the comparison, since actual subjects have missing data
while their digital twins do not. To correct for this, for each covariate we mean impute the
missing data for actual subjects based upon the baseline values. For each subject, we assign
the corresponding mean-imputed covariate values to their digital twins, meaning missingness
or the imputed value cannot be used to differentiate subjects or their digital twins.
We make the comparisons using unregularized logistic regression for C. The models are
evaluated using 5-fold cross validation, and we repeat the evaluation for 100 trials, using a
different digital twin of each subject for each trial. For each trial, we generate a digital twin
for each subject and perform the mean imputation procedure described above, taking the
relevant single visit or visit change data. We split the data into 5 mutually exclusive folds,
each containing approximately 20% of the data. For each fold, we hold it out and combine
the data from the 4 other folds and train a logistic regression model, evaluating the AUC
on the held out fold. We average the AUC values over the 5 folds and report the result for
the trial. The mean and standard deviation of these mean AUC values over trials is shown
in Figure 6.
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